Comment
doi: 10.1056/NEJMp048143.
The price tag on progress--chemotherapy for colorectal cancer
Affiliations
- PMID: 15269308
- DOI: 10.1056/NEJMp048143
Item in Clipboard
Comment
The price tag on progress--chemotherapy for colorectal cancer
N Engl J Med.
.
No abstract available
Comment in
-
Cetuximab in colon cancer.N Engl J Med. 2004 Oct 7;351(15):1575-6; author reply 1575-6. doi: 10.1056/NEJM200410073511519. N Engl J Med. 2004. PMID: 15470223 No abstract available.
-
Cetuximab in colon cancer.N Engl J Med. 2004 Oct 7;351(15):1575-6; author reply 1575-6. N Engl J Med. 2004. PMID: 15473023 No abstract available.
-
Cetuximab in colon cancer.N Engl J Med. 2004 Oct 7;351(15):1575-6; author reply 1575-6. N Engl J Med. 2004. PMID: 15473024 No abstract available.
Comment on
-
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.N Engl J Med. 2004 Jul 22;351(4):337-45. doi: 10.1056/NEJMoa033025. N Engl J Med. 2004. PMID: 15269313 Clinical Trial.
Similar articles
-
Cetuximab in colon cancer.N Engl J Med. 2004 Oct 7;351(15):1575-6; author reply 1575-6. N Engl J Med. 2004. PMID: 15473023 No abstract available.
-
Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?Oncologist. 2015 Sep;20(9):981-2. doi: 10.1634/theoncologist.2015-0028. Epub 2015 Aug 11. Oncologist. 2015. PMID: 26265225 Free PMC article.
-
Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis.J Chemother. 2006 Oct;18(5):532-7. doi: 10.1179/joc.2006.18.5.532. J Chemother. 2006. PMID: 17127231
-
[Progress of chemotherapy in colorectal cancer].Gan To Kagaku Ryoho. 2007 Nov;34(11):1771-6. Gan To Kagaku Ryoho. 2007. PMID: 18064761 Review. Japanese. No abstract available.
-
New combinations in metastatic colorectal cancer: what are our expectations?Oncologist. 2005 May;10(5):320-2. doi: 10.1634/theoncologist.10-5-320. Oncologist. 2005. PMID: 15851788 Review. No abstract available.
Cited by
-
Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10.Br J Cancer. 2012 Feb 28;106(5):883-8. doi: 10.1038/bjc.2012.27. Epub 2012 Feb 7. Br J Cancer. 2012. PMID: 22315050 Free PMC article.
-
Common sense for a common problem: the question of screening the average-risk population for colorectal neoplasia.Can J Surg. 2005 Dec;48(6):431-2. Can J Surg. 2005. PMID: 16417047 Free PMC article. No abstract available.
-
Economics of cancer care.J Oncol Pract. 2007 May;3(3):113-4. doi: 10.1200/JOP.0731501. J Oncol Pract. 2007. PMID: 20859394 Free PMC article. No abstract available.
-
Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer.Curr Oncol. 2019 Oct;26(5):e597-e609. doi: 10.3747/co.26.4843. Epub 2019 Oct 1. Curr Oncol. 2019. PMID: 31708653 Free PMC article.
-
Preference values associated with stage III colon cancer and adjuvant chemotherapy.Qual Life Res. 2010 Apr;19(3):391-400. doi: 10.1007/s11136-010-9589-5. Qual Life Res. 2010. PMID: 20084462
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
